The Goldman Sachs Group Begins Coverage on ImmunoGen (NASDAQ:IMGN)

The Goldman Sachs Group began coverage on shares of ImmunoGen (NASDAQ:IMGN – Free Report) in a research report released on Monday morning, Marketbeat reports. The brokerage issued a neutral rating and a $17.00 price target on the biotechnology company’s stock. Several other analysts have also recently weighed in on the company. BMO Capital Markets lifted […]

Leave a Reply

Your email address will not be published.

Previous post Genius Sports Limited (NYSE:GENI) Receives $9.32 Average Price Target from Analysts
Next post Marin Software (NASDAQ:MRIN) Earns Hold Rating from Analysts at